Literature DB >> 7908472

Reversal of xylazine-induced sedation in dairy calves with atipamezole: a field trial.

J M Arnemo1, N E Søli.   

Abstract

Dairy calves immobilized with xylazine (XYL) were given atipamezole-HCl (ATI) at different XYL:ATI dose ratios (w/w) for reversal and the antagonistic effect of xylazine was evaluated. Control animals received saline for comparison. Intramuscular administration of xylazine (0.139-0.357 mg/kg) induced sedation with complete immobilization in all animals (n = 195) and there were no spontaneous recoveries before injection of atipamezole or saline. Atipamezole was given 10-81 min and saline 25 min after xylazine administration. Intramuscular administration of atipamezole at XYL:ATI dose ratios of 5:2 (n = 11), 10:3 (n = 21), 4:1 (n = 21) and 5:1 (n = 25) effectively antagonized the xylazine-induced immobilization and sedation. The mean times (standard deviation) from injection of atipamezole until the animals were standing for these dose ratio groups were 6.09 (3.12), 5.15 (2.87), 6.35 (2.54) and 7.86 (3.11) min, respectively. The mean time to standing for control animals (n = 11) was 94.1 (3.0) min. Intravenous administration of atipamezole at XYL:ATI dose ratios of 10:3 (n = 7), 4:1 (n = 33), 5:1 (n = 16), 8:1 (n = 27) and 10:1 (n = 9) rapidly reversed the xylazine-induced immobilization and sedation. The mean times (standard deviation) from injection of atipamezole until the animals were standing for these dose ratio groups were 0.98 (0.22), 1.32 (0.48), 1.09 (0.34), 1.39 (0.52) and 1.60 (0.69) min, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7908472     DOI: 10.1007/bf01839221

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  9 in total

1.  A case report of the treatment of an overdose of xylazine in a cow.

Authors:  D C Van Metre
Journal:  Cornell Vet       Date:  1992-07

Review 2.  Xylazine--a review of its pharmacology and use in veterinary medicine.

Authors:  S A Greene; J C Thurmon
Journal:  J Vet Pharmacol Ther       Date:  1988-12       Impact factor: 1.786

3.  Sympatho-adrenal activity and the clinical sedative effect of detomidine in horses.

Authors:  M Raekallio; A Leino; O Vainio; M Scheinin
Journal:  Equine Vet J Suppl       Date:  1992-02

4.  Effects of atipamezole on xylazine sedation in ponies.

Authors:  S P Luna; N J Beale; P M Taylor
Journal:  Vet Rec       Date:  1992-03-28       Impact factor: 2.695

Review 5.  Injectable anesthetic agents and techniques in ruminants and swine.

Authors:  J C Thurmon
Journal:  Vet Clin North Am Food Anim Pract       Date:  1986-11       Impact factor: 3.357

6.  Antagonistic effect of atipamezole on xylazine-induced sedation, bradycardia, and ruminal atony in calves.

Authors:  J R Thompson; K W Kersting; W H Hsu
Journal:  Am J Vet Res       Date:  1991-08       Impact factor: 1.156

7.  Reversal of xylazine sedation in dogs.

Authors:  N Jarvis; G C England
Journal:  Vet Rec       Date:  1991-04-06       Impact factor: 2.695

8.  Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole.

Authors:  R Virtanen; J M Savola; V Saano
Journal:  Arch Int Pharmacodyn Ther       Date:  1989 Jan-Feb

9.  Influence of yohimbine on xylazine-induced depression of central nervous, gastrointestinal and cardiovascular function in the calf.

Authors:  C L Guard; W S Schwark
Journal:  Cornell Vet       Date:  1984-10
  9 in total
  2 in total

1.  Chemical capture of free-ranging cattle: immobilization with xylazine or medetomidine, and reversal with atipamezole.

Authors:  J M Arnemo; N E Søli
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

2.  Technological, environmental and biological factors: referent variance values for infrared imaging of the bovine.

Authors:  Yuri R Montanholi; Melissa Lim; Alaina Macdonald; Brock A Smith; Christy Goldhawk; Karen Schwartzkopf-Genswein; Stephen P Miller
Journal:  J Anim Sci Biotechnol       Date:  2015-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.